Niraparib

Niraparib

Niraparib (trade name Zejula) is an orally active small molecule PARP inhibitor developed by Tesaro to treat ovarian cancer. Niraparib has been approved by US FDA on March27, 2017.

Specifications

Product Name:                  Niraparib

Synonyms:                         MK-4827; (S)-2-(4-(Piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide

CAS Number:                     1038915-60-4

Molecular Weight:            320.3932

Molecular Formula:          C19H20N4O

Purity (HPLC):                     ≥95%

Shipping Conditions:         Room temperature.

Storage Conditions:           Refrigerated.

Regulatory Statement:      For Research Use Only.

SMILES:                               NC(=O)c1cccc2c1nn(c2)c1ccc(cc1)[C@@H]1CCCNC1

  • $200.00
  • Ex Tax: $200.00

Available Options